Oral Therapy Options for Relapsing-Remitting Multiple Sclerosis

The patient symptoms that help neurologists distinguish relapsing and remitting multiple sclerosis from other forms of the disease, and recommendations regarding the best timing to initiate therapy.

The rationale for early treatment initiation for patients with relapsing-remitting multiple sclerosis.

Best practices for talking about treatment goals and options with patients who have relapsing-remitting multiple sclerosis.

Considerations that affect recommendations for novel oral treatment for relapsing-remitting multiple sclerosis vs a more conventional option.

Experts discuss types of oral fumarates that are available to treat relapsing-remitting multiple sclerosis, and best practices for selecting an option based on trial data and clinical experience.

What to know about using S1P receptor modulators as oral therapy for relapsing-remitting multiple sclerosis.

Considerations that affect which S1P receptor modulator may be used to treat relapsing-remitting multiple sclerosis, and how to best utilize them during COVID-19.

The advantages of using the pyrimidine synthesis inhibitor teriflunomide to treat relapsing-remitting multiple sclerosis.

Characteristics that make the purine antimetabolite, cladribine, a unique treatment option for relapsing-remitting multiple sclerosis.

Following previous discussions about novel oral therapies available as treatment for relapsing-remitting multiple sclerosis, a small panel of neurologists comment on factors that affect which agent they select.

The types of tests used to monitor response to novel oral therapies used in relapsing-remitting multiple sclerosis.

The patient factors and other variables that impact first-line treatment decisions in relapsing-remitting multiple sclerosis.

Key takeaways from a larger discussion surrounding the utilization of novel oral agents as therapy for patients with relapsing-remitting multiple sclerosis.